Request Demo
Last update 26 Feb 2026
Perindopril/Indapamide
Last update 26 Feb 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Biprel, Coverex-AS KombForte, Coversyl Plus + [11] |
Target |
Action inhibitors |
Mechanism ACE inhibitors(Angiotensin-converting enzyme inhibitors), Symporters inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (07 Sep 2005), |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC35H48ClN5O8S |
InChIKeyLRRJSCKXFJTRLC-MHXJNQAMSA-N |
CAS Registry182176-83-6 |
Related
12
Clinical Trials associated with Perindopril/IndapamideCTR20250879
培哚普利吲达帕胺片在健康研究参与者中的随机、开放、单剂量、双周期、自身交叉空腹及餐后生物等效性试验
[Translation] A randomized, open-label, single-dose, two-period, self-crossover fasting and fed bioequivalence trial of perindopril indapamide tablets in healthy study participants
CTR20250386
随机、开放、单剂量、两制剂、两序列、交叉对照设计，评价空腹及餐后状态下单次口服受试制剂培哚普利吲达帕胺片与参比制剂培哚普利吲达帕胺片（商品名：百普乐®）在中国健康受试者中的生物等效性正式试验
[Translation] A formal trial of a randomized, open-label, single-dose, two-formulation, two-sequence, crossover controlled design to evaluate the bioequivalence of a single oral dose of the test formulation, perindopril indapamide tablets, and the reference formulation, perindopril indapamide tablets (trade name: Bipro®) in healthy Chinese subjects under fasting and fed conditions
CTR20231821
培哚普利吲达帕胺片在健康受试者中的随机、开放、单剂量、双周期、自身交叉空腹及餐后状态下生物等效性试验
[Translation] A randomized, open-label, single-dose, two-period, self-crossover bioequivalence study of perindopril indapamide tablets in healthy subjects under fasting and fed conditions
100 Clinical Results associated with Perindopril/Indapamide
Login to view more data
100 Translational Medicine associated with Perindopril/Indapamide
Login to view more data
100 Patents (Medical) associated with Perindopril/Indapamide
Login to view more data
153
Literatures (Medical) associated with Perindopril/Indapamide01 May 2025BMJ Open Diabetes Research & Care
Relationship between time-varying achieved HbA1c and risk of coronary artery disease events among common haptoglobin phenotype groups with type 2 diabetes: the ADVANCE study
Article
Author: Woodward, Mark ; Mancia, Giuseppe ; Marre, Michel ; Sapp, John ; Carew, Allie S ; Samuel, Michelle ; Harris, Katie ; Selvin, Elizabeth ; Warren, Rachel A ; Chalmers, John ; Lavallée, Samantha K ; Rimm, Eric ; Levy, Andrew P ; Harrap, Stephen ; Cahill, Leah E ; Poulter, Neil
Introduction:
This study sought to determine whether the association between attaining specific glycated hemoglobin (HbA1c) targets (<7.0% (<53 mmol/mol) and ≥8.0% (≥64 mmol/mol) compared with 7.0%–7.9%) over time and risk of incident coronary artery disease (CAD) was dependent on haptoglobin (Hp) phenotype in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study.
Research design and methods:
Prospectively collected HbA1c data from the ADVANCE biomarker case-cohort study, updated at 6 months and every 12 months thereafter over a median of 5.0 (IQR 4.5–5.3) years, were analyzed in relation to incident CAD in the Hp2-2 (n=1323) and non-Hp2-2 (n=2069) phenotypes separately using weighted multivariable-adjusted Cox regression models. Additional a priori stratifications by sex, race, previous cardiovascular disease (CVD), and type 2 diabetes duration were performed.
Results:
Mean HbA1c was similar in each phenotype group throughout the study. Compared with HbA1c of 7.0%–7.9%, HbA1c <7.0% was not associated with CAD risk for any phenotype group or subgroup. HbA1c ≥8.0% compared with 7.0%–7.9% over time was associated with higher CAD risk for the Hp2-2 phenotype only (HR 1.53, 95% CI 1.01 to 2.32; no significant association in the non-Hp2-2 type: 1.26, 0.89 to 1.77, p-interaction=0.71); this was pronounced when those with previous CVD at baseline were excluded (Hp2-2: 2.80, 1.41 to 5.53, p-interaction=0.03). Compared with HbA1c of <8.0%, having HbA1c ≥8.0% was associated with a 59% higher CAD risk among participants with the Hp2-2 phenotype (1.59, 1.12 to 2.26) and a 39% higher CAD risk among participants without the Hp2-2 phenotype (1.39, 1.03 to 1.88, p-interaction=0.97).
Conclusions:
The present ADVANCE analysis suggests that not having HbA1c ≥8.0%, rather than achieving HbA1c <7.0%, was found to be particularly important for CAD prevention among people with type 2 diabetes and the common Hp2-2 phenotype. While the subgroup analyses were likely underpowered, their inclusion is hypothesis generating and can be used in future meta-analyses to improve power and generalizability.
01 Feb 2025DIABETES CARE
Intensive Glucose Lowering and Its Effects on Vascular Events and Death According to Age at Diagnosis and Duration of Diabetes: The ADVANCE Trial
Article
Author: Poulter, Neil ; Zoungas, Sophia ; Woodward, Mark ; Harris, Katie ; Mancia, Giuseppe ; Harrap, Stephen ; Ohkuma, Toshiaki ; Marre, Michel ; Chalmers, John ; Hamet, Pavel
OBJECTIVE:
To compare the vascular effects of pursuing more versus less glucose lowering in patients with younger or older age at diabetes diagnosis, and with shorter or longer diabetes duration.
RESEARCH DESIGN AND METHODS:
We studied 11,138 participants from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial, classified into subgroups defined by age at diabetes diagnosis (≤50, >50–60, and >60 years) and diabetes duration (≤5, >5–10, and >10 years).
RESULTS:
Intensive glucose lowering significantly lowered the risk of the primary composite outcome of major macrovascular and microvascular events (hazard ratio 0.90, 95% CI 0.82–0.98) with no evidence of heterogeneity in the proportional effects across subgroups defined by age at diagnosis or diabetes duration (P for heterogeneity = 0.86 and 0.47, respectively). Similar consistent treatment effects were also observed for all-cause death, cardiovascular death, and the components of major vascular events.
CONCLUSIONS:
Intensive glucose lowering may be recommended irrespective of age at diagnosis or diabetes duration.
01 Jan 2025Cerebral circulation - cognition and behavior
Effect of randomised blood pressure lowering treatment and intensive glucose control on dementia and cognitive decline according to baseline cognitive function and other subpopulations of individuals with type 2 diabetes: Results from the ADVANCE trial
Article
Author: Poulter, Neil ; Marre, Michel ; Mancia, Giuseppe ; MacMahon, Stephen ; Woodward, Mark ; Xu, Ying ; Anderson, Craig ; Gong, Jessica ; Harris, Katie ; Chalmers, John ; Hamet, Pavel ; Harrap, Stephen ; Shajahan, Sultana
Background and aims:
Accumulating evidence indicates that reducing high blood pressure (BP) prevents dementia and mild cognitive impairment (MCI). Furthermore, although diabetes is a risk factor for dementia and MCI, there is uncertainty of the effect of intensive glucose control on these endpoints. This study aimed to determine the effects of BP-lowering (vs placebo) and intensive glucose-lowering (vs standard control) treatments according to baseline cognition and other characteristics on dementia and cognitive decline (CD) in people with type 2 diabetes mellitus (T2DM).
Methods:
The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial involved 11,140 individuals with T2DM. The effects of BP-lowering and intensive glucose-lowering treatments were explored in subgroups of baseline Mini-Mental State Examination (MMSE), categorised as cognitively normal (scores ≥28) and cognitive impairment (scores <28). The primary outcome was a composite of dementia/CD that accounted for the competing risk of death. Multinomial regression models, adjusted for common cardiovascular risk factors, were used to estimate odds ratios (OR) with 95 % confidence intervals (CI) of the effects of the treatments on dementia/CD. Homogeneity of effects by subgroups were evaluated using interaction terms in the models. A two-sided p value <0.05 was regarded as statistically significant.
Results:
BP-lowering treatment (vs. placebo) was associated with a lower odds of dementia/CD in participants with cognitive impairment (OR 0.76, 95 % CI (0.59-0.99)) but not in those cognitively normal (OR 1.05, 95 % CI (0.92-1.21); p for interaction 0.03). Those with a history of cardio-renal-metabolic syndrome did not experience a benefit of active BP lowering treatment compared with placebo on dementia/CD. There were no further subgroup effects of BP-lowering treatment. The effect of intensive glucose lowering (vs standard control) on the odds of dementia/CD did not vary by baseline cognition subgroup. However, it did vary by level of blood glucose at baseline (<7.9 mmol/L OR 1.12, 95 % CI (0.96-1.30) vs ≥ 7.9 mmol/L 0.87 (0.75-1.00); p for interaction 0.02) and duration of T2DM (<10 years OR 0.92 (0.81-1.05) vs ≥10 years 1.16 (0.97-1.38); p for interaction 0.04).
Conclusions:
This study suggests greater effects of BP-lowering treatment in those with early loss of cognitive function than in those cognitively normal. There were also differential effects of intensive glucose-lowering on dementia and CD according to levels of blood glucose and duration of diabetes in people with T2DM.
Clinical trial registration:
ADVANCE is registered with ClinicalTrials.gov: number NCT00145925.
100 Deals associated with Perindopril/Indapamide
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hypertension | China | 07 Sep 2005 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Angina, Unstable | Phase 3 | China | 01 Jun 2001 | |
| Angina, Unstable | Phase 3 | Australia | 01 Jun 2001 | |
| Angina, Unstable | Phase 3 | Canada | 01 Jun 2001 | |
| Angina, Unstable | Phase 3 | Netherlands | 01 Jun 2001 | |
| Angina, Unstable | Phase 3 | United Kingdom | 01 Jun 2001 | |
| Diabetes Mellitus, Type 2 | Phase 3 | China | 01 Jun 2001 | |
| Diabetes Mellitus, Type 2 | Phase 3 | Australia | 01 Jun 2001 | |
| Diabetes Mellitus, Type 2 | Phase 3 | Canada | 01 Jun 2001 | |
| Diabetes Mellitus, Type 2 | Phase 3 | Netherlands | 01 Jun 2001 | |
| Diabetes Mellitus, Type 2 | Phase 3 | United Kingdom | 01 Jun 2001 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | - | Active BP lowering treatment (combination perindopril±indapamide) | zgflvugbvb(baokrspoye) = ldkecqmvgt nshmyhpaqe (sdnkdjotii ) | - | 01 Mar 2023 | ||
Placebo | zgflvugbvb(baokrspoye) = cwjnuwfkvk nshmyhpaqe (sdnkdjotii ) | ||||||
Phase 3 | 9,694 | huuhseghnw(lqvvcsauoa): 0.91 (95% CI, 0.83 - 1.0), P-Value = 0.04 | - | 01 Aug 2022 | |||
Placebo | |||||||
Phase 3 | 682 | (Intensive blood glucose control) | iqfruljikn(nriiuceiiq) = whbsacwmfl roaqtzoson (cnwpkjytzf, -20.2%, - 0.9%) View more | - | 16 Apr 2022 | ||
(Intensive blood pressure control) | hwffjvgnmd(hmccxujfnu) = zzuhiueuuu udjgqzjklf (nhkfbvtpsg, -8.9 to 3.6) | ||||||
Phase 3 | 11,140 | ffgggkevek(fwegvjzkmv) = njkjktayuk ospccfeult (iagptrukcm, 6.15 - 10.63) | - | 25 May 2021 | |||
Phase 3 | 11,140 | shagieoput(qpzxnyqsrd): 0.78 (95% CI, 0.71 - 0.86) | - | 20 Apr 2021 | |||
Placebo | |||||||
Phase 3 | 9,195 | (³30% decrease in UACR) | jrfpeuxpyw(fedbsbawcd): HR = 0.1 (95% CI, 0.01 - 0.79) | Positive | 03 Nov 2015 | ||
(<30% decrease to <30% increase in UACR) | |||||||
Not Applicable | - | xnmjoianso(vdswmzqekp): 0.91 (95% CI, 0.84 - 0.99), P-Value = 0.03 | - | 09 Oct 2014 | |||
Placebo | |||||||
Phase 3 | 11,140 | (Normal cognitive function) | wtlzwzklks(nhlgcilwvz): HR = 1.33 (95% CI, 1.16 - 1.54), P-Value = < 0.03 View more | - | 01 Nov 2009 | ||
(Mild cognitive dysfunction) | |||||||
Phase 3 | - | dbtuozysdm(benpbffkwm) = jflfqfnpvq sxxtxyoocu (buzkltxijs, 12 - 50) | - | 01 Nov 2009 | |||
zbrpsdwakd(kfsamgzymc) = nhhskqvzig njkufrnbgr (velsmkobez, 1 - 32) View more | |||||||
Phase 3 | 11,140 | vdmnoweyih(fcwjfmaawn) = ldkvgoemjc txmipbeydw (aamporfzas ) | - | 08 Sep 2007 | |||
Placebo | vdmnoweyih(fcwjfmaawn) = rwatbsxrln txmipbeydw (aamporfzas ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free